Clinical Trial Update: Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study of Brisdelle (paroxetine mesylate) after single and multiple oral doses in healthy postmenopausal women.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Menopause

Drugs mentioned

• Brisdelle (paroxetine mesylate)

Snippet

Sponsor: Noven Therapeutics | Conditions: Postmenopausal Symptoms | Phase 1 | Status: COMPLETED | Results posted: 2014-02-24